Pharmacological treatment of heart failure with reduced ejection fraction

Topic: Heart failure

• Mineralocorticoid antagonists (MRAs)
• Angiotensin receptor blockers (ARBs)
• Angiotensin-converting enzyme inhibitors (ACE-I) 
• Angiotensin receptor–neprilysin inhibitors (ARNIs)
• Sacubitril/valsartan
• Beta-blockers
• Digoxin
• Diuretics, loop
• I_f  channel blockers
• Ivabradine
• Omega-3 polyunsaturated fatty acids (N-3PUFAs) 
• Vasodilators
• Hydralazine
• Isosorbide dinitrate

References

1. Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer, ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
   Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128